Seven scientists at the Department of Energy’s Oak Ridge National Laboratory have been named Battelle Distinguished Inventors, in recognition of their obtaining 14 or more patents during their careers at the lab.
Three researchers at ORNL have been named ORNL Corporate Fellows in recognition of significant career accomplishments and continued leadership in their scientific fields.
ORNL has been selected to lead an Energy Frontier Research Center, or EFRC, focused on polymer electrolytes for next-generation energy storage devices such as fuel cells and solid-state electric vehicle batteries.
ORNL Corporate Fellow and Center for Nanophase Materials Sciences researcher Bobby Sumpter has been named fellow of two scientific professional societies: the Institute of Physics and the International Association of Advanced Materials.
ORNL researchers have developed an upcycling approach that adds value to discarded plastics for reuse in additive manufacturing, or 3D printing.
ORNL, TVA and TNECD were recognized by the Federal Laboratory Consortium for their impactful partnership that resulted in a record $2.3 billion investment by Ultium Cells, a General Motors and LG Energy Solution joint venture, to build a battery cell manufacturing plant in Spring Hill, Tennessee.
Muralidharan was recognized for “a highly prolific spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on the quality of life, economic development and welfare of society.”
Scientists at the Department of Energy’s Oak Ridge National Laboratory have created a recipe for a renewable 3D printing feedstock that could spur a profitable new use for an intractable biorefinery byproduct: lignin.
Scientists at the Department of Energy’s Oak Ridge National Laboratory used neutrons, isotopes and simulations to “see” the atomic structure of a saturated solution and found evidence supporting one of two competing hypotheses about how ions come
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.